Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells

Carcinogenesis

Volumn 26, Issue 11, 2005, Pages 1896-1904

  Hsu, Jocelyn C ^a   Zhang, Joann ^a   Dev, Anurupa ^a   Wing, Aimee ^a   Bjeldanes, Leonard F ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; ANTIANDROGEN; LUCIFERASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BROCCOLI; CABBAGE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DIMERIZATION; DRUG PROTEIN BINDING; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTICARCINOGENIC AGENTS; CELL PROLIFERATION; CHLORAMPHENICOL; DOWN-REGULATION; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INDOLES; LUCIFERASES; MALE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 27744484361     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi155     Document Type: Article

References (48)

1. Ruijter,E., van de Kaa,C., Miller,G., Ruiter,D., Debruyne,F. and Schalken,J. (1999) Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev., 20, 22-45.
2. Wingo,P.A., Cardinez,C.J., Landis,S.H., Greenlee,R.T., Ries,L.A., Anderson,R.N. and Thun,M.J. (2003) Long-term trends in cancer mortality in the United States, 1930-1998. Cancer, 97, 3133-3275.
3. Hirsch,P.J. (2001) Current concepts in the treatment of prostate cancer. N. J. Med., 98, 11.
4. Sogani,P.C. and Fair,W.R. (1987) Treatment of advanced prostatic cancer. Urol. Clin. North Am., 14, 353-371.
5. Labrie,F., Dupont,A., Belanger,A., Cusan,L., Brochu,M., Turina,E., Pinault,S., Lacourciere,Y. and Emond,J. (1989) Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br. J. Urol., 63, 634-638.
6. Veldscholte,J., Ris-Stalpers,C., Kuiper,G.G., Jenster,G., Berrevoets,C., Claassen,E., van Rooij,H.C., Trapman,J., Brinkmann,A.O. and Mulder,E. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173, 534-540.
7. Grigoryev,D.N., Long,B.J., Njar,V.C. and Brodie,A.H. (2000) Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol., 75, 1-10.
8. Suzuki,H., Sato,N., Watabe,Y., Masai,M., Seino,S. and Shimazaki,J. (1993) Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46, 759-765.
9. Veldscholte,J., Berrevoets,C.A., Ris-Stalpers,C., Kuiper,G.G., Jenster,G., Trapman,J., Brinkmann,A.O. and Mulder,E. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol., 41, 665-669.
10. Chen,I., Safe,S. and Bjeldanes,L. (1996) Indole-3-carbinol and diindolyl-methane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem. Pharmacol., 51, 1069-1076.
11. Morse,M.A., LaGreca,S.D., Amin,S.G. and Chung,F.L. (1990) Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice. Cancer Res., 50, 2613-2617.
12. Srivastava,B. and Shukla,Y. (1998) Antitumour promoting activity of indole-3-carbinol in mouse skin carcinogenesis. Cancer Lett., 134, 91-95.
13. Vang,O., Jensen,M.B. and Autrup,H. (1990) Induction of cytochrome P450IA1 in rat colon and liver by indole-3-carbinol and 5,6-benzoflavone. Carcinogenesis, 11, 1259-1263.
14. Yuan,F., Chen,D.Z., Liu,K., Sepkovic,D.W., Bradlow,H.L. and Auborn,K. (1999) Anti-estrogenic activities of indole-3-carbinol in cervical cells: Implication for prevention of cervical cancer. Anticancer Res., 19, 1673-1680.
15. Wong,G.Y., Bradlow,L., Sepkovic,D., Mehl,S., Mailman,J. and Osborne,M.P. (1997) Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. Cell. Biochem. Suppl., 28-29, 111-116.
16. Block,G., Patterson,B. and Subar,A. (1992) Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr. Cancer, 18, 1-29.
17. Birt,D.F., Pelling,J.C., Nair,S. and Lepley,D. (1996) Diet intervention for modifying cancer risk. Prog. Clin. Biol. Res., 395, 223-234.
18. Bradlow,H.L., Michnovicz,J., Telang,N.T. and Osborne,M.P. (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis, 12, 1571-1574.
19. Chen,I., McDougal,A., Wang,F. and Safe,S. (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis, 19, 1631-1639.
20. Michnovicz,J.J. and Bradlow,H.L. (1990) Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J. Natl Cancer Inst., 82, 947-949.
21. 1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem., 273, 3838-3847.
22. Cram,E.J., Liu,B.D., Bjeldanes,L.F. and Firestone,G.L. (2001) Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J. Biol. Chem., 276, 22332-22340.
23. 1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer, 98, 2511-2520.
24. Vicini,F.A., Kestin,L.L. and Martinez,A.A. (2000) The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer, 88, 2305-2318.
25. Vicini,F.A., Horwitz,E.M., Gonzalez,J. and Martinez,A.A. (1997) Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J. Urol., 158, 319-325.
26. Polascik,T.J., Oesterling,J.E. and Partin,A.W. (1999) Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J. Urol., 162, 293-306.
27. Oesterling,J.E. (1991) Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145, 907-923.
28. Hobisch,A., Culig,Z., Radmayr,C., Bartsch,G., Klocker,H. and Hittmair,A. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55, 3068-3072.
29. Tilley,W.D., Wilson,C.M., Marcelli,M. and McPhaul,M.J. (1990) Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res., 50, 5382-5386.
30. Culig,Z. (2003) Role of the androgen receptor axis in prostate cancer. Urology, 62, 21-26.
31. Craft,N., Shostak,Y., Carey,M. and Sawyers,C.L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5, 280-285.
32. Culig,Z., Bartsch,G. and Hobisch,A. (2002) Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol., 197, 231-238.
33. Nazareth,L.V. and Weigel,N.L. (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem., 271, 19900-19907.
34. Le,H.T., Schaldach,C.M., Firestone,G.L. and Bjeldanes,L.F. (2003) Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J. Biol. Chem., 278, 21136-21145.
35. Tilley,W.D., Marcelli,M. and McPhaul,M.J. (1990) Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J. Biol. Chem., 265, 13776-13781.
36. Kaisary,A.V., Tyrrell,C.J., Peeling,W.B. and Griffiths,K. (1991) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br. J. Urol., 67, 502-508.
37. Tyrrell,C.J., Denis,L., Newling,D., Soloway,M., Channer,K. and Cockshott,I.D. (1998) Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur. Urol., 33, 39-53.
38. Fowler,J.E.Jr, Gottesman,J.E., Reid,C.F., Andriole,G.L.Jr and Soloway,M.S. (2000) Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J. Urol., 164, 730-734.
39. Watson,R. and Soloway,M.S. (1996) Is there a role for induction androgen deprivation prior to radical prostatectomy? Hematol. Oncol. Clin. North Am., 10, 627-641.
40. Yeh,S., Lin,H.K., Kang,H.Y., Thin,T.H., Lin,M.F. and Chang,C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA, 96, 5458-5463.
41. Kang,H.Y., Lin,H.K., Hu,Y.C., Yeh,S., Huang,K.E. and Chang,C. (2001) From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl Acad. Sci. USA, 98, 3018-3023.
42. Yeh,S., Hu,Y.C., Rahman,M., Lin,H.K., Hsu,C.L., Ting,H.J., Kang,H.Y. and Chang,C. (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl Acad. Sci. USA, 97, 11256-11261.
43. Miyamoto,H., Yeh,S., Wilding,G. and Chang,C. (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl Acad. Sci. USA, 95, 7379-7384.
44. Yeh,S., Miyamoto,H., Shima,H. and Chang,C. (1998) From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc. Natl Acad. Sci. USA, 95, 5527-5532.
45. Mitchell,S.H., Zhu,W. and Young,C.Y. (1999) Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res., 59, 5892-5895.
46. Ren,F., Zhang,S., Mitchell,S.H., Butler,R. and Young,C.Y. (2000) Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene, 19, 1924-1932.
47. (1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis, 23, 1297-1305.
48. Riegman,P.H., Vlietstra,R.J., van der Korput,J.A., Brinkmann,A.O. and Trapman,J. (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5, 1921-1930.